Overview

Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide

Status:
Completed

Trial end date:
2020-02-27

Target enrollment:

Participant gender:

Summary

This research trial studies molecular features and pathways in predicting drug resistance in patients with castration-resistant prostate cancer that has spread to other parts of the body and who are receiving enzalutamide. Studying samples of blood and tissue in the laboratory from patients receiving enzalutamide may help doctors learn more about molecular features and pathways that may cause prostate cancer to be resistant to the drug.

Details

Lead Sponsor:

OHSU Knight Cancer Institute

Collaborators:

National Cancer Institute (NCI)
Oregon Health and Science University
United States Department of Defense